Dapagliflozin (DrugBank: Dapagliflozin)
2 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
49 | Systemic lupus erythematosus | 1 |
222 | Primary nephrotic syndrome | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | ChiCTR1800015030 | 2018-03-01 | 2018-03-01 | A Clinical Trial on Safety and effect of Dapagliflozin to Control Blood Glucose Levels in Systemic Lupus Erythematosus | The Safety of SGLT2-i Dapagliflozin on Treating Blood Glucose Levels in SLE | Systemic Lupus Erythematosus | Case series:add-on or replace dapagliflozin; | Dept. Rheumatology, Renji Hospital South Campus | NULL | Pending | 18 | 70 | Both | Case series:35; | 4 (Phase 4 study) | China |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02585804 (ClinicalTrials.gov) | September 2015 | 22/10/2015 | Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects | Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects: The TRANSLATE Study | Focal Segmental Glomerulosclerosis | Drug: Dapagliflozin | University Health Network, Toronto | AstraZeneca;University of Toronto;Toronto General Hospital | Completed | 18 Years | N/A | All | 10 | Phase 4 | Canada |